Obesity
4 Results found
Highlight of the month
Clinical Paper Summary: Bacus et al, 2024. Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product
This retrospective review evaluates real world clinical experience of concomitant use of meal replacement products and GLP-1 RAs in Australia and South Africa. The results illustrate that this combination for weight management is feasible in real-life and may offer potential advantages for weight management.
See more
This study aimed to determine the demographic, eating, self‐efficacy and program engagement characteristics of VLCD users in Australia (regular vs. intermittent users) and associations with self‐perceived program success on weight loss, quality of life (QOL), mental health and physical health.
Learn about new Australian clinical evidence on the impact of the very low energy diets for Type 2 Diabetes remission. The DiRECT-Aus trial confirms that that an intensive lifestyle intervention (very low energy diet) delivered in an Australian primary care setting to individuals with recently diagnosed type 2 diabetes results in remission for one in two participants. The study was supported by Diabetes Australia (not-for-profit organisation), and 5 public health networks. Nestlé Health Science donated OPTIFAST VLCD product for the duration of the trial. Click here to view the video.
Proceedings from a webinar from the 81st American Diabetes Association discusses the current and emerging novel non-pharmacological approaches to the prevention and remission of type 2 diabetes, weight management, and CV risk reduction.